Evidence map›Paper›PMID 36340602›Full record

ArticleExperimental and therapeutic medicine2022

A pan‑cancer analysis of RCC2 and its interaction with HMGA2 protein in an in vitro model of colorectal cancer cells.

Guiyuan Gu, Yuhong Wang, Yucheng Shen, Yan Ma, Hongli Yang, Shan Huang, Lin Hu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Guiyuan GuDepartment of Pathology, The Affiliated Hai'an Hospital of Nantong University, Nantong, Jiangsu 226601, P.R. China.
Yuhong WangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Yucheng ShenDepartment of Oncology, The Affiliated Hai'an Hospital of Nantong University, Nantong, Jiangsu 226601, P.R. China.
Yan MaDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Hongli YangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Shan HuangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Lin HuInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215000, P.R. China.
First Affiliated Hospital of Soochow University · CNAffiliated Hospital of Nantong University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulator of chromosome condensation 2 (RCC2) is highly involved in the development of tumor malignancies. The underlying mechanisms remain to be elucidated. The present study aimed to explore the role of RCC2 in the development of tumor malignancies and explore the underlying mechanisms in colorectal cancer (CRC). RCC2 expression and survival analysis were performed in human pan-cancer. The results of searching its mRNA expression in The Cancer Genome Atlas (TCGA) database showed that RCC2 was highly expressed in different types of cancer. High RCC2 expression levels were significantly correlated with poor survival outcomes by the Kaplan-Meier analysis in the TCGA database. Immunohistochemistry revealed that RCC2 was higher expressed in 36 CRC tissues than in adjacent normal tissues. Co-immunoprecipitation revealed that RCC2 bound to high mobility group A2 (HMGA2). Ectopic expression of RCC2 promoted cell proliferation, migration and invasion, whereas knockdown of HMGA2 exerted the opposite effects. Collectively, the data provided a novel biomarker of RCC2 in various types of cancer. High RCC2 expression levels were correlated with poor prognosis in different types of cancer. In addition, RCC2 may combine with HMGA2 to promote CRC malignancy.

Indexed as

biomarkerscancer prognosishigh mobility group A2receiver operating characteristicregulator of chromosome condensation 2

Identifiers

PMID36340602
PMCPMC9627563
OpenAlexW4306874648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.